STOCK TITAN

Celldex Therapeutics Inc. - CLDX STOCK NEWS

Welcome to our dedicated news page for Celldex Therapeutics (Ticker: CLDX), a resource for investors and traders seeking the latest updates and insights on Celldex Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Celldex Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Celldex Therapeutics's position in the market.

Rhea-AI Summary
Celldex Therapeutics, Inc. (CLDX) to participate in fireside chat at Evercore ISI HealthCONx Conference. Webcast and replay details provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.36%
Tags
conferences
-
Rhea-AI Summary
Celldex Therapeutics, Inc. (CLDX) Announces Pricing of Public Offering at $27.00 per Share, Expects Gross Proceeds of $200.5 Million. Jefferies, Leerink Partners, Guggenheim Securities, and Cantor are the Joint Book-Running Managers
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.68%
Tags
-
Rhea-AI Summary
Celldex Therapeutics, Inc. (Nasdaq: CLDX) Announces Proposed Public Offering of Common Stock to Fund Clinical Development
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.68%
Tags
Rhea-AI Summary
Celldex Therapeutics, Inc. announced positive topline results from their Phase 2 clinical trial of barzolvolimab in patients with chronic spontaneous urticaria (CSU). The study showed statistically significant decreases in urticaria disease activity across multiple dose groups, with a mean change from baseline to week 12 of -23.87 in the 300 mg q8w dose group and -23.02 in the 150 mg q4w dose group. Barzolvolimab was well tolerated with a favorable safety profile. The company plans to continue treatment for 52 weeks and move towards registrational trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.97%
Tags
-
Rhea-AI Summary
Celldex Therapeutics announces positive results from Phase 1b study of barzolvolimab in prurigo nodularis (PN), a chronic skin disease causing intensely itchy lumps. Single IV dose of 3.0 mg/kg barzolvolimab resulted in rapid and durable reductions in itch and healing of skin lesions. Phase 2 study to initiate in early 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Celldex Therapeutics completes Phase 2 CSU enrollment ahead of schedule and plans to present topline data by the end of the year. Phase 1b PN study results met internal hurdle for advancement. Enrollment continues for Phase 2 studies in chronic inducible urticaria and eosinophilic esophagitis. Financial highlights include $235.3 million cash position and $1.5 million total revenue in Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.2%
Tags
Rhea-AI Summary
Celldex Therapeutics announces acceptance of abstract on Phase 1b study of barzolvolimab in prurigo nodularis at WCI
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.59%
Tags
-
Rhea-AI Summary
Celldex to participate in fireside chat at Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.53%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.83%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.46%
Tags
Celldex Therapeutics Inc.

Nasdaq:CLDX

CLDX Rankings

CLDX Stock Data

2.58B
52.74M
0.35%
96.8%
9.98%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Hampton

About CLDX

celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. celldex therapeutics (nasdaq: cldx) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. the company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. this has created a leading pipeline in im